ATTOHealthcare · Biotechnology

ATTO Stock Forecast: Attovia Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026

$15

−0.52% on the day

The 5 Wall Street analysts covering Attovia Therapeutics, Inc. hold a median 12-month price target of $45 — +196.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 0 of 100 as at 31 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$693.4M

Ticker Nerd rank

0/ 100

Median analyst target

$45

Analysts covering

Revenue$450K−99.9% y/y

Operating income−$21.8M

Net income−$20.7M

Free cash flow−$16.9M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+9.8%

−11.4%

From high

−40.5%

From low

+10.6%

$14

$26

Range since 5 Aug 2026, adjusted closes · the dot is the last close

Ticker Nerd rank

ATTO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Attovia Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026

0/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Revisions

Value

Accruals

Growth

Issuance

Quality

Volatility

Momentum

Size (48): Smaller than most of the companies we track.

Momentum (1): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ATTO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ATTO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 5 Aug 2026Adjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts

5 Buy0 Hold0 Sell

Low $30Median $45High $52

The green dot is the last close — the median target sits +196.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 6 moved it down.

Date	Firm	Action	Rating	Target
31 Aug 2026	Citigroup	Initiates	Buy	—
31 Aug 2026	Leerink Partners	Initiates	Outperform	—
31 Aug 2026	LifeSci Capital	Initiates	Outperform	—
31 Aug 2026	Morgan Stanley	Initiates	Overweight	—
31 Aug 2026	RBC Capital	Initiates	Outperform	—
15 Aug 2022	Barrington Research	Maintains	Outperform	$32 → $15
5 July 2022	Goldman Sachs	Maintains	Neutral	$28 → $14
21 Sept 2021	Goldman Sachs	Upgrade	Neutral	$11 → $30
25 Nov 2020	Baird	Maintains	Outperform	—
25 Nov 2020	Bank of America	Maintains	Neutral	—
25 Nov 2020	Barrington Research	Initiates	Outperform	—
25 Nov 2020	Credit Suisse	Downgrade	Neutral	—
25 Nov 2020	Goldman Sachs	Downgrade	Sell	—
25 Nov 2020	Morgan Stanley	Downgrade	Equal-Weight	—
30 Apr 2020	Goldman Sachs	Downgrade	Sell	—
5 June 2019	Morgan Stanley	Downgrade	Equal-Weight	$8.00 → $3.00
8 Nov 2018	Baird	Maintains	Outperform	$10 → $8.00
30 July 2018	Baird	Maintains	Outperform	$12 → $10
3 Apr 2018	Goldman Sachs	Initiates	Neutral	—
21 Mar 2018	Baird	Maintains	Outperform	$14 → $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ATTO appears in the Radar on the weeks it earns a place.

Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

The AI build-out map

PDF

AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST

Performance

ATTO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

ATTO vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ATTO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year

Analysts raising

Analysts cutting

Fundamentals

Attovia Therapeutics, Inc. (ATTO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −6.4×
Price / sales: 385.2×
Price / book: −4.5×
EV / EBITDA: −11.2×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): −99.9%
Gross margin: —
Operating margin: −4845.1%
Net margin: 0.0%

Returns & dividend

Return on equity: 56.7%
Return on assets: −36.7%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Attovia Therapeutics, Inc. (ATTO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Attovia Therapeutics, Inc. has a market value of $693.4M and an enterprise value of $840.9M.
Revenue in the twelve months to 30 June 2026: $450K.
Net income over the same four quarters: −$68.9M, a −15318.4% net margin.
Diluted earnings per share, trailing twelve months: $−2.37.
Shares outstanding: 43.0M.
Trailing P/E: −6.4×; forward P/E: −6.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Attovia Therapeutics, Inc. employs 44 people — $10K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 1 Nov 2026

Data provided by Twelve Data

Peers

ATTO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
ATTOAttovia Therapeutics, Inc.	$693.4M	0
WVEWave Life Sciences, Inc.	$690.6M	21
SGMTSagimet Biosciences, Inc.	$697.8M	44
ACHVAchieve Life Sciences, Inc.	$701.2M	36
APMDApnimed, Inc.	$682.6M	1
SLBTSL Science Holding Ltd.	$672.9M	0
DNAGinkgo Bioworks Holdings, Inc.	$726.0M	43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Attovia Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ATTO news & analysis

Attovia Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewsWire · 27 Oct 2026neutral

Attovia Therapeutics announced that management will participate in three upcoming investor conferences: a Guggenheim fireside chat on November 10 and meetings at the Stifel and Jefferies healthcare conferences on November 11 and November 16–18, 2026. The Guggenheim chat will be webcast in the Events & Presentations section of the company’s website.

Why it matters — The announcement provides ATTO watchers with dates and formats for upcoming management appearances, including a webcast.

Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026

GlobeNewsWire · 28 Sept 2026positive

Attovia Therapeutics announced it will present new clinical, translational, and preclinical data across its pipeline, including ATTO-1310 and ATTO-2306, at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and the Fall Clinical Dermatology Conference 2026.

Why it matters — Investors tracking ATTO would care because upcoming presentations of pipeline data at major dermatology conferences could provide new insight into the company's development programs.

Attovia Therapeutics, Inc. (ATTO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 16 Sept 2026neutral

Attovia Therapeutics, Inc. (ATTO) presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha.

Why it matters — ATTO watchers would care because the transcript offers insight into the company's presentation and messaging delivered at a major healthcare investment conference.

FAQ

Frequently asked questions about ATTO stock

What is the ATTO stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Attovia Therapeutics, Inc. have a median 12-month price target of $45, with estimates ranging from $30 to $52. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ATTO stock a buy right now?

Of the 5 analysts covering Attovia Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Attovia Therapeutics, Inc. 0 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ATTO?

As at 31 Oct 2026, Attovia Therapeutics, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (48 of 100).

Will ATTO stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +196.2% from the last close, and Ticker Nerd's factor model ranks Attovia Therapeutics, Inc. 0 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ATTO stock forecast for 2030?

No analyst covering Attovia Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATTO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $52 over the next 12 months.

What does Attovia Therapeutics, Inc. do?

Attovia Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing precision biologics for immune-mediated diseases.

What is the latest news on ATTO?

The most recent item we track (GlobeNewsWire, 27 Oct 2026): "Attovia Therapeutics to Participate in Upcoming Investor Conferences". Attovia Therapeutics announced that management will participate in three upcoming investor conferences: a Guggenheim fireside chat on November 10 and meetings at the Stifel and Jefferies healthcare conferences on November 11 and November 16–18, 2026. The Guggenheim chat will be webcast in the Events & Presentations section of the company’s website.

Company

About Attovia Therapeutics, Inc.

Attovia Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing precision biologics for immune-mediated diseases. The company’s core work centers on its ATTOBODY platform, which is designed to create multispecific protein therapies that target multiple disease pathways involved in inflammation and immune dysfunction. Its current pipeline includes candidates for dermatology conditions such as atopic dermatitis and chronic pruritus, as well as gastroenterology and inflammatory disorders, including inflammatory bowel disease. Attovia Therapeutics Inc. develops therapeutic programs aimed at areas with significant unmet medical need, using a platform-based approach intended to improve specificity and broaden treatment options across several disease areas. The company is based in San Carlos, California.

CEO Mr. Tao Fu M.B.A., M.S. · 44 employees · United States · https://www.attovia.com